Partially ablative radiotherapy (PAR) for large mass tumors using simultaneous integrated boost: A dose-escalation feasibility study

Savino Cilla, Francesco Deodato, Anna Ianiro, Gabriella Macchia, Vincenzo Picardi, Milly Buwenge, Silvia Cammelli, Alice Zamagni, Vincenzo Valentini, Alessio G. Morganti

Research output: Contribution to journalArticle

Abstract

Purpose: This study aimed to assess the feasibility to plan and deliver highly heterogeneous doses to symptomatic large tumors using volumetric modulated arc therapy (VMAT) and simultaneous integrated boost (SIB) during a short course palliative accelerated radiotherapy. Methods: A patient with a large symptomatic chordoma infiltrating the right gluteal region was selected. A modified SIB treatment was implemented to irradiate the central volume of the tumor (boost target volume, BTV) up to 10 Gy/fraction in a dose escalation trial while maintaining the remaining tumor volume (planning target volume, PTV) and the surrounding healthy tissues within 5 Gy/fraction in twice daily fractions for two consecutive days. Four SIB plans were generated in the dual-arc modality; a basal dose of 20 Gy was prescribed to the PTV, while the BTV was boosted up to 40 Gy. For comparison purposes, plans obtained with a sequential boost (SEQ plans) were also generated. All plans were optimized to deliver at least 95% of the prescription dose to the targets. Dose contrast index (DCI), conformity index (CI), integral dose (ID), and the irradiated body volumes at 5, 10, and 20 Gy were evaluated. Results: At equal targets coverage, SIB plans provided major improvement in DCI, CI, and ID with respect to SEQ plans. When BTV dose escalated up to 200% of PTV prescription, DCI resulted in 66% for SIB plans and 37% for SEQ plans; the ID increase was only 11% for SIB plans (vs 27% for SEQ plans) and the increase in healthy tissues receiving more than 5, 10, and 20 Gy was less than 2%. Pretreatment dose verification reported a γ-value passing rate greater than 95% with 3%(global)-2 mm. Conclusion: A modified SIB technique is dosimetrically feasible for large tumors, where doses higher than the tolerance dose of healthy tissues are necessary to increase the therapeutic gain.

Original languageEnglish
Pages (from-to)35-43
Number of pages9
JournalJournal of Applied Clinical Medical Physics
Volume19
Issue number6
DOIs
Publication statusPublished - Nov 1 2018

Fingerprint

Radiotherapy
Feasibility Studies
acceleration (physics)
Tumors
radiation therapy
tumors
Tumor Burden
dosage
Prescriptions
Tissue
Planning
Chordoma
Intensity-Modulated Radiotherapy
Neoplasms
Buttocks
planning
Therapeutics
arcs
pretreatment
therapy

Keywords

  • palliative
  • simultaneous integrated boost
  • VMAT

ASJC Scopus subject areas

  • Radiation
  • Instrumentation
  • Radiology Nuclear Medicine and imaging

Cite this

Partially ablative radiotherapy (PAR) for large mass tumors using simultaneous integrated boost : A dose-escalation feasibility study. / Cilla, Savino; Deodato, Francesco; Ianiro, Anna; Macchia, Gabriella; Picardi, Vincenzo; Buwenge, Milly; Cammelli, Silvia; Zamagni, Alice; Valentini, Vincenzo; Morganti, Alessio G.

In: Journal of Applied Clinical Medical Physics, Vol. 19, No. 6, 01.11.2018, p. 35-43.

Research output: Contribution to journalArticle

Cilla, Savino ; Deodato, Francesco ; Ianiro, Anna ; Macchia, Gabriella ; Picardi, Vincenzo ; Buwenge, Milly ; Cammelli, Silvia ; Zamagni, Alice ; Valentini, Vincenzo ; Morganti, Alessio G. / Partially ablative radiotherapy (PAR) for large mass tumors using simultaneous integrated boost : A dose-escalation feasibility study. In: Journal of Applied Clinical Medical Physics. 2018 ; Vol. 19, No. 6. pp. 35-43.
@article{167689a7e71d4baba568ead89b02619a,
title = "Partially ablative radiotherapy (PAR) for large mass tumors using simultaneous integrated boost: A dose-escalation feasibility study",
abstract = "Purpose: This study aimed to assess the feasibility to plan and deliver highly heterogeneous doses to symptomatic large tumors using volumetric modulated arc therapy (VMAT) and simultaneous integrated boost (SIB) during a short course palliative accelerated radiotherapy. Methods: A patient with a large symptomatic chordoma infiltrating the right gluteal region was selected. A modified SIB treatment was implemented to irradiate the central volume of the tumor (boost target volume, BTV) up to 10 Gy/fraction in a dose escalation trial while maintaining the remaining tumor volume (planning target volume, PTV) and the surrounding healthy tissues within 5 Gy/fraction in twice daily fractions for two consecutive days. Four SIB plans were generated in the dual-arc modality; a basal dose of 20 Gy was prescribed to the PTV, while the BTV was boosted up to 40 Gy. For comparison purposes, plans obtained with a sequential boost (SEQ plans) were also generated. All plans were optimized to deliver at least 95{\%} of the prescription dose to the targets. Dose contrast index (DCI), conformity index (CI), integral dose (ID), and the irradiated body volumes at 5, 10, and 20 Gy were evaluated. Results: At equal targets coverage, SIB plans provided major improvement in DCI, CI, and ID with respect to SEQ plans. When BTV dose escalated up to 200{\%} of PTV prescription, DCI resulted in 66{\%} for SIB plans and 37{\%} for SEQ plans; the ID increase was only 11{\%} for SIB plans (vs 27{\%} for SEQ plans) and the increase in healthy tissues receiving more than 5, 10, and 20 Gy was less than 2{\%}. Pretreatment dose verification reported a γ-value passing rate greater than 95{\%} with 3{\%}(global)-2 mm. Conclusion: A modified SIB technique is dosimetrically feasible for large tumors, where doses higher than the tolerance dose of healthy tissues are necessary to increase the therapeutic gain.",
keywords = "palliative, simultaneous integrated boost, VMAT",
author = "Savino Cilla and Francesco Deodato and Anna Ianiro and Gabriella Macchia and Vincenzo Picardi and Milly Buwenge and Silvia Cammelli and Alice Zamagni and Vincenzo Valentini and Morganti, {Alessio G.}",
year = "2018",
month = "11",
day = "1",
doi = "10.1002/acm2.12427",
language = "English",
volume = "19",
pages = "35--43",
journal = "Journal of Applied Clinical Medical Physics",
issn = "1526-9914",
publisher = "American Institute of Physics Publising LLC",
number = "6",

}

TY - JOUR

T1 - Partially ablative radiotherapy (PAR) for large mass tumors using simultaneous integrated boost

T2 - A dose-escalation feasibility study

AU - Cilla, Savino

AU - Deodato, Francesco

AU - Ianiro, Anna

AU - Macchia, Gabriella

AU - Picardi, Vincenzo

AU - Buwenge, Milly

AU - Cammelli, Silvia

AU - Zamagni, Alice

AU - Valentini, Vincenzo

AU - Morganti, Alessio G.

PY - 2018/11/1

Y1 - 2018/11/1

N2 - Purpose: This study aimed to assess the feasibility to plan and deliver highly heterogeneous doses to symptomatic large tumors using volumetric modulated arc therapy (VMAT) and simultaneous integrated boost (SIB) during a short course palliative accelerated radiotherapy. Methods: A patient with a large symptomatic chordoma infiltrating the right gluteal region was selected. A modified SIB treatment was implemented to irradiate the central volume of the tumor (boost target volume, BTV) up to 10 Gy/fraction in a dose escalation trial while maintaining the remaining tumor volume (planning target volume, PTV) and the surrounding healthy tissues within 5 Gy/fraction in twice daily fractions for two consecutive days. Four SIB plans were generated in the dual-arc modality; a basal dose of 20 Gy was prescribed to the PTV, while the BTV was boosted up to 40 Gy. For comparison purposes, plans obtained with a sequential boost (SEQ plans) were also generated. All plans were optimized to deliver at least 95% of the prescription dose to the targets. Dose contrast index (DCI), conformity index (CI), integral dose (ID), and the irradiated body volumes at 5, 10, and 20 Gy were evaluated. Results: At equal targets coverage, SIB plans provided major improvement in DCI, CI, and ID with respect to SEQ plans. When BTV dose escalated up to 200% of PTV prescription, DCI resulted in 66% for SIB plans and 37% for SEQ plans; the ID increase was only 11% for SIB plans (vs 27% for SEQ plans) and the increase in healthy tissues receiving more than 5, 10, and 20 Gy was less than 2%. Pretreatment dose verification reported a γ-value passing rate greater than 95% with 3%(global)-2 mm. Conclusion: A modified SIB technique is dosimetrically feasible for large tumors, where doses higher than the tolerance dose of healthy tissues are necessary to increase the therapeutic gain.

AB - Purpose: This study aimed to assess the feasibility to plan and deliver highly heterogeneous doses to symptomatic large tumors using volumetric modulated arc therapy (VMAT) and simultaneous integrated boost (SIB) during a short course palliative accelerated radiotherapy. Methods: A patient with a large symptomatic chordoma infiltrating the right gluteal region was selected. A modified SIB treatment was implemented to irradiate the central volume of the tumor (boost target volume, BTV) up to 10 Gy/fraction in a dose escalation trial while maintaining the remaining tumor volume (planning target volume, PTV) and the surrounding healthy tissues within 5 Gy/fraction in twice daily fractions for two consecutive days. Four SIB plans were generated in the dual-arc modality; a basal dose of 20 Gy was prescribed to the PTV, while the BTV was boosted up to 40 Gy. For comparison purposes, plans obtained with a sequential boost (SEQ plans) were also generated. All plans were optimized to deliver at least 95% of the prescription dose to the targets. Dose contrast index (DCI), conformity index (CI), integral dose (ID), and the irradiated body volumes at 5, 10, and 20 Gy were evaluated. Results: At equal targets coverage, SIB plans provided major improvement in DCI, CI, and ID with respect to SEQ plans. When BTV dose escalated up to 200% of PTV prescription, DCI resulted in 66% for SIB plans and 37% for SEQ plans; the ID increase was only 11% for SIB plans (vs 27% for SEQ plans) and the increase in healthy tissues receiving more than 5, 10, and 20 Gy was less than 2%. Pretreatment dose verification reported a γ-value passing rate greater than 95% with 3%(global)-2 mm. Conclusion: A modified SIB technique is dosimetrically feasible for large tumors, where doses higher than the tolerance dose of healthy tissues are necessary to increase the therapeutic gain.

KW - palliative

KW - simultaneous integrated boost

KW - VMAT

UR - http://www.scopus.com/inward/record.url?scp=85053462360&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85053462360&partnerID=8YFLogxK

U2 - 10.1002/acm2.12427

DO - 10.1002/acm2.12427

M3 - Article

C2 - 30220111

AN - SCOPUS:85053462360

VL - 19

SP - 35

EP - 43

JO - Journal of Applied Clinical Medical Physics

JF - Journal of Applied Clinical Medical Physics

SN - 1526-9914

IS - 6

ER -